Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Kodiak Sciences Inc Common Stock

Vantage Biosciences is developing a novel, oral treatment for inflammatory conditions by targeting the root drivers of inflammation. The company focuses on transforming diabetic retinopathy care.

Vantage Biosciences

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc.

Kodiak Sciences is a biopharmaceutical company researching, developing and commercializing therapeutics for retinal diseases.

Kodiak Sciences

Kodiak Sciences | 9,017 followers on LinkedIn. We are a clinical stage biopharma company bringing new science to prevent and treat high prevalence retinal diseases. | Kodiak is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak&#39;s discovery engine.

CEO at Xencor

Bassil Dahiyat

Jean Drouin

Gayathrie Janakiraman

Kim Williams

We look forward to participating in a presentation and panel at #InnovateRetina2024 today. See below for details and we look forward to seeing you there! Slides of the presentation will be made available at the beginning of the presentation here: https://lnkd.in/g-w8vFD4

Join us at 10:30am ET today for our Investor R&D Day! The event can be accessed virtually at: https://lnkd.in/gS2_MUKz

We look forward to hosting our Investor R&D Day on Monday, September 23 at 10:30am ET! “We look forward to addressing the most common questions we’ve received from investors about Kodiak today and sharing how we believe our learnings, our course corrections, and our rapid execution will help us move forward,” said Dr. Victor Perlroth, M.D., Chief Executive Officer. Register here for the webcast: https://lnkd.in/gmCRNV28 For more details see our press release: https://lnkd.in/gjfKXc63

Join us tomorrow at 8am ET at the Goldman Sachs 45th Annual Global Healthcare conference. We look forward to providing an update on our tarcocimab tedromer, KSI-501 and KSI-101 clinical programs. A live webcast of the presentation will be available here: https://lnkd.in/evfm2VPr

On June 8, we look forward to presenting important updates on our late-phase clinical program in retina at this year’s Clinical Trials at the Summit meeting. To all those attending, we hope to see you there!

Today is #ClinicalTrialsDay and in honor of all the investigators and participants in our clinical trials and in others, we want to say thank you! We admire and recognize all that you have done to advance vision care around the world. Learn more about CTD2024 by the Association of Clinical Research Professionals (ACRP) here: https://lnkd.in/e9r9k5Wu

We continue to progress our late- and early-phase retina pipeline programs. Learn more in our latest press release: https://lnkd.in/emWeNWr3

We recently reported fourth quarter and full year 2023 financial results and highlighted important updates about our three clinical programs. Read the full press release here: https://lnkd.in/gm7gZmgQ

We look forward to kicking off the new year by sharing an update on Kodiak’s clinical pipeline in retina at the 42nd Annual J.P. Morgan Healthcare Conference. Tune in tomorrow at 10:30 am ET. A live webcast of the presentation will be available here: https://lnkd.in/g3MyHiVB

We look forward to speaking today at the 6th annual Evercore ISI HealthCONx conference! Tune into the live webcast at 3:25pm EST to learn more about Kodiak’s latest developments: https://lnkd.in/g-w8vFD4

Metric
Company Name	Kodiak Sciences Inc Common Stock	Vantage Biosciences
Symbol	KOD
MSH ID	COM:KODIAK	COM:VANTAGE-BIOSCIENCES
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	GB
Stage		Seed
Employee Count	108
Website	kodiak.com	vantage-biosciences.com
LinkedIn		vantage-biosciences
Founders

Metric
Market Cap	325.74M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:KODIAK

Kodiak Sciences

Last Close

5.90

22/11 21:00

Market Cap

132.39M

Beta: -

Volume Today

251.42K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue